Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Open-label clinical trial of alendronate after teriparatide therapy in people with spinal cord injury and low bone mineral density.

Haider IT, Simonian N, Saini AS, Leung FM, Edwards WB, Schnitzer TJ.

Spinal Cord. 2019 Jun 4. doi: 10.1038/s41393-019-0303-3. [Epub ahead of print]

PMID:
31164732
2.

Bone fragility after spinal cord injury: reductions in stiffness and bone mineral at the distal femur and proximal tibia as a function of time.

Haider IT, Lobos SM, Simonian N, Schnitzer TJ, Edwards WB.

Osteoporos Int. 2018 Dec;29(12):2703-2715. doi: 10.1007/s00198-018-4733-0. Epub 2018 Oct 17.

PMID:
30334093
3.

Effects of Teriparatide and Vibration on Bone Mass and Bone Strength in People with Bone Loss and Spinal Cord Injury: A Randomized, Controlled Trial.

Edwards WB, Simonian N, Haider IT, Anschel AS, Chen D, Gordon KE, Gregory EK, Kim KH, Parachuri R, Troy KL, Schnitzer TJ.

J Bone Miner Res. 2018 Oct;33(10):1729-1740. doi: 10.1002/jbmr.3525. Epub 2018 Jun 28.

PMID:
29905973
4.

Assessment of Paraspinal Muscle Cross-sectional Area After Lumbar Decompression: Minimally Invasive Versus Open Approaches.

Bresnahan LE, Smith JS, Ogden AT, Quinn S, Cybulski GR, Simonian N, Natarajan RN, Fessler RD, Fessler RG.

Clin Spine Surg. 2017 Apr;30(3):E162-E168. doi: 10.1097/BSD.0000000000000038.

PMID:
28323694
5.

US immigration order strikes against biotech.

Levin JM, Holtzman SH, Maraganore J, Hastings PJ, Cohen R, Dahiyat B, Adams J, Adams C, Ahrens B, Albers J, Aspinall MG, Audia JE, Babler M, Barrett P, Barry Z, Bermingham N, Bloch S, Blum RI, Bolno PB, Bonney MW, Booth B, Bradbury DM, Brauer SK, Byers B, Cagnoni PJ, Cali BM, Ciechanover I, Clark C, Clayman MD, Cleland JL, Cobb P, Cooper R, Currie MG, Diekman J, Dobmeier EL, Doerfler D, Donley EL, Dunsire D, During M, Eckstein JW, Elenko E, Exter NA, Fleming JJ, Flesher GJ, Formela JF, Forrester R, Francois C, Franklin H, Freeman MW, Furst H, Gage LP, Galakatos N, Gallagher BM, Geraghty JA, Gill S, Goeddel DV, Goldsmith MA, Gowen M, Goyal V, Graney T, Grayzel D, Greene B, Grint P, Gutierrez-Ramos JC, Haney B, Ha-Ngoc T, Harris T, Hasnain F, Hata YS, Hecht P, Henshaw L, Heyman R, Hoppenot H, Horvitz HR, Hughes TE, Hutton WS, Isaacs ST, Jenkins A, Jonker J, Kaplan J, Karsen P, Keiper J, Kim J, Kindler J, King R, King V, Kjellson N, Koenig S, Koenig G, Kolchinsky P, Laikind P, Langer RB, Lee JJ, Leff JS, Leicher BA, Leschly N, Levin A, Levin M, Levine AJ, Levy A, Liu DR, Lodish HF, Lopatin U, Love TW, Macdonald G, Maderis GJ, Mahadevia A, Mahanthappa NK, Martin JF, Martin A, Martucci WE, McArthur JG, McCann CM, McCarthy SA, McDonough CG, Mendlein J, Miller L, Miralles D, Moch KI, More B, Myers AG, Narachi MA, Nashat A, Nelson W, Newell WJ, Olle B, Osborn JE, Owens JC, Pande A, Papadopoulos S, Parker HS, Parmar KM, Patterson MR, Paul SM, Perez R, Perry M, Pfeffer CG, Powell M, Pruzanski M, Purcell DJ, Rakhit A, Ramamoorthi K, Rastetter W, Rawcliffe AA, Reid LE, Renaud RC, Rhodes JP, Rieflin WJ, Robins C, Rocklage SM, Rosenblatt M, Rosin JG, Rutter WJ, Saha S, Samuels C, Sato VL, Scangos G, Scarlett JA, Schenkein D, Schreiber SL, Schwab A, Sekhri P, Shah R, Shenk T, Siegall CB, Simon NJ, Simonian N, Stein J, Su M, Szela MT, Taglietti M, Tandon N, Termeer H, Thornberry NA, Tolar M, Ulevitch R, Vaishnaw AK, VanLent A, Varsavsky M, Vlasuk GP, Vounatsos M, Waksal SG, Warma N, Watts RJ, Werber Y, Westphal C, Wierenga W, Williams DE, Williams LR, Xanthopoulos KG, Zohar D, Zweifach SS.

Nat Biotechnol. 2017 Mar 7;35(3):204-206. doi: 10.1038/nbt.3824. No abstract available.

PMID:
28267733
6.

Zoledronic Acid Treatment After Acute Spinal Cord Injury: ResultsĀ of a Randomized, Placebo-Controlled Pilot Trial.

Schnitzer TJ, Kim K, Marks J, Yeasted R, Simonian N, Chen D.

PM R. 2016 Sep;8(9):833-43. doi: 10.1016/j.pmrj.2016.01.012. Epub 2016 Jan 30.

PMID:
26828618
7.

Reduction in Torsional Stiffness and Strength at the Proximal Tibia as a Function of Time Since Spinal Cord Injury.

Edwards WB, Simonian N, Troy KL, Schnitzer TJ.

J Bone Miner Res. 2015 Aug;30(8):1422-30. doi: 10.1002/jbmr.2474. Epub 2015 May 21.

8.

The effect of call on neurosurgery residents' skills: implications for policy regarding resident call periods.

Ganju A, Kahol K, Lee P, Simonian N, Quinn SJ, Ferrara JJ, Batjer HH.

J Neurosurg. 2012 Mar;116(3):478-82. doi: 10.3171/2011.9.JNS101406. Epub 2011 Dec 2.

PMID:
22136645
9.

Negative differential resistance at sequential single-electron tunnelling through atoms and molecules.

Simonian N, Li J, Likharev K.

Nanotechnology. 2007 Oct 24;18(42):424006. doi: 10.1088/0957-4484/18/42/424006. Epub 2007 Sep 13.

PMID:
21730439
10.

Oculomotor function in chronic traumatic brain injury.

Kraus MF, Little DM, Donnell AJ, Reilly JL, Simonian N, Sweeney JA.

Cogn Behav Neurol. 2007 Sep;20(3):170-8.

PMID:
17846516
11.

Glycoprotein IIb/IIIa inhibitor therapy and outcomes after percutaneous coronary intervention.

Tepper RI, Simonian N.

Am J Cardiol. 2003 Sep 15;92(6):771-2. No abstract available.

PMID:
12972136
12.

Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis.

Miller DM, Rudick RA, Baier M, Cutter G, Doughtery DS, Weinstock-Guttman B, Mass MK, Fisher E, Simonian N.

Mult Scler. 2003 Feb;9(1):1-5.

PMID:
12617260
13.

Eight-year follow-up study of brain atrophy in patients with MS.

Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee JC, Miller D, Weinstock-Guttman B, Mass MK, Dougherty DS, Simonian NA.

Neurology. 2002 Nov 12;59(9):1412-20.

PMID:
12427893
14.

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN; IMPACT Investigators.

Neurology. 2002 Sep 10;59(5):679-87.

PMID:
12221157
15.

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997.

Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Granger CV, Simon JH, Alam JJ, Simonian NA, Campion MK, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Weistock-Guttman B, Whitham RH; Multiple Sclerosis Collaborative Research Group.

Neurology. 2001 Dec;57(12 Suppl 5):S25-30. No abstract available.

PMID:
11902591
16.

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ, Kniker JE, Kooijmans MF, Lull JM, Sandrock AW, Simon JH, Simonian NA, Whitaker JN.

Arch Neurol. 2001 Jun;58(6):961-7.

PMID:
11405811
17.

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.

Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, Mass MK, Miller D, Simonian NA.

Neurology. 2001 May 22;56(10):1324-30.

PMID:
11376182
18.

Self-reported visual dysfunction in multiple sclerosis: results from the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25).

Balcer LJ, Baier ML, Kunkle AM, Rudick RA, Weinstock-Guttman B, Simonian N, Galetta SL, Cutter GR, Maguire MG.

Mult Scler. 2000 Dec;6(6):382-5.

PMID:
11212133
19.

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients.

Fisher E, Rudick RA, Cutter G, Baier M, Miller D, Weinstock-Guttman B, Mass MK, Dougherty DS, Simonian NA.

Mult Scler. 2000 Dec;6(6):373-7.

PMID:
11212131
20.

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW.

N Engl J Med. 2000 Sep 28;343(13):898-904.

21.

A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group.

Simon JH, Lull J, Jacobs LD, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Sheeder J, Miller D, McCabe K, Serra A, Campion MK, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE 3rd.

Neurology. 2000 Jul 25;55(2):185-92.

PMID:
10908888
22.

A Wallerian degeneration pattern in patients at risk for MS.

Simon JH, Kinkel RP, Jacobs L, Bub L, Simonian N.

Neurology. 2000 Mar 14;54(5):1155-60.

PMID:
10720290
23.

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

Simon JH, Jacobs LD, Campion MK, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Miller DE, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE 3rd, Brownscheidle CM.

Neurology. 1999 Jul 13;53(1):139-48.

PMID:
10408550
24.

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, Herndon RM, Salazar AM, Fischer JS, Granger CV, Goodkin DE, Simon JH, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munchsauer FE, O'Reilly K, Priore RL, Whitham RH, et al.

J Neuroimmunol. 1999 Jan 1;93(1-2):8-14.

PMID:
10378864
25.

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.

Rogge MC, Simonian NA, Jones WE.

Eur J Neurol. 1999 May;6(3):375-7. No abstract available.

PMID:
10210923
26.

"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis.

Simonian NA, McAllister A, Lull J.

J Neurol Neurosurg Psychiatry. 1999 Apr;66(4):553-4. No abstract available.

27.

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE 3rd, Cookfair DL, Simon JH, Jacobs LD.

Neurology. 1998 May;50(5):1266-72.

PMID:
9595973
28.

Pleural effusion, hepatitis and hemolytic anemia in a twelve-year-old male child.

Simonian N, Janner D.

Pediatr Infect Dis J. 1998 Feb;17(2):173-4, 176-7. No abstract available.

PMID:
9493823
29.

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie M, Martens-Davidson AL, Meyer M, Sheeder J, Choi K, Scherzinger AL, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Whitham RH, et al.

Ann Neurol. 1998 Jan;43(1):79-87.

PMID:
9450771
31.

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Granger CV, Simon JH, Alam JJ, Simonian NA, Campion MK, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Whitham RH, et al.

Neurology. 1997 Aug;49(2):358-63.

PMID:
9270562
32.

Effects of nifedipine and nicardipine on regional cerebral blood flow distribution in patients with arterial hypertension.

Akopov SE, Simonian NA, Kazarian AV.

Methods Find Exp Clin Pharmacol. 1996 Dec;18(10):685-92.

PMID:
9121225
33.

Kainic acid induces apoptosis in neurons.

Simonian NA, Getz RL, Leveque JC, Konradi C, Coyle JT.

Neuroscience. 1996 Dec;75(4):1047-55.

PMID:
8938740
34.

Kainate induces apoptosis in neurons.

Simonian NA, Getz RL, Leveque JC, Konradi C, Coyle JT.

Neuroscience. 1996 Oct;74(3):675-83.

PMID:
8884764
35.
36.

Oxidative stress in neurodegenerative diseases.

Simonian NA, Coyle JT.

Annu Rev Pharmacol Toxicol. 1996;36:83-106. Review.

PMID:
8725383
37.

Functional alterations in neural circuits in Alzheimer's disease.

Simonian NA, Hyman BT.

Neurobiol Aging. 1995 May-Jun;16(3):305-9. Review.

PMID:
7566339
38.
39.

Calcium/calmodulin-dependent protein kinase II immunostaining is preserved in Alzheimer's disease hippocampal neurons.

Simonian NA, Elvhage T, Czernik AJ, Greengard P, Hyman BT.

Brain Res. 1994 Sep 19;657(1-2):294-9.

PMID:
7820630
40.
41.

Functional integrity of neural systems related to memory in Alzheimer's disease.

Simonian NA, Rebeck GW, Hyman BT.

Prog Brain Res. 1994;100:245-54. Review. No abstract available.

PMID:
7938525
42.

Ifosfamide causes a diazepam-sensitive encephalopathy.

Simonian NA, Gilliam FG, Chiappa KH.

Neurology. 1993 Dec;43(12):2700-2.

PMID:
8255482
43.

Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in the hippocampal formation.

Simonian NA, Hyman BT.

J Neuropathol Exp Neurol. 1993 Nov;52(6):580-5.

PMID:
8229076
44.

Leptomeningeal myelomatosis presenting with mental status changes and other neurologic findings.

Leifer D, Grabowski T, Simonian N, Demirjian ZN.

Cancer. 1992 Oct 1;70(7):1899-904. Review.

PMID:
1525764
45.

Specific infection of central nervous system white matter by a variant of gross murine leukemia virus.

Simonian NA, Rosenthal LA, Korostoff J, Hickey WF, Blank KJ, Gaulton GN.

Virology. 1990 Jul;177(1):384-7.

PMID:
2353463
46.

Lupus anticoagulants, anticardiolipin antibodies, and cerebral ischemia.

Kushner M, Simonian N.

Stroke. 1989 Feb;20(2):225-9.

PMID:
2493172
47.

[Effect of laser radiation and combined ionizing and laser radiation on the cell-division time of bacteria].

Simonian NV, Voskanian KSh.

Radiobiologiia. 1988 Mar-Apr;28(2):262-4. Russian.

PMID:
3283825
48.

[Relation between the radioprotective effect of helium-neon laser radiation on bacterial cells and the time period between 2 types of irradiation].

Voskanian KSh, Simonian NV, Avakian TsM, Avakian GM.

Radiobiologiia. 1987 Sep-Oct;27(5):708-11. Russian.

PMID:
3313507
49.

[Modification of the damaging effect of alpha-particles on Escherichia coli K-12 by low-intensity laser irradiation].

Voskanian KSh, Simonian NV, Avakian TsM, Arutiunian AG.

Radiobiologiia. 1986 May-Jun;26(3):375-7. Russian.

PMID:
3526394
50.

[Effect of helium-neon laser radiation on the radiosensitivity of Escherichia coli K-12 cells].

Voskanian KSh, Simonian NV, Avakian TsM, Arutiunian AG.

Radiobiologiia. 1985 Jul-Aug;25(4):557-60. Russian.

PMID:
3898212

Supplemental Content

Loading ...
Support Center